Insider Transactions in Q3 2021 at Bei Gene, Ltd. (BGNE)
Insider Transaction List (Q3 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 28
2021
|
Lai Wang Global Head of R&D |
SELL
Bona fide gift
|
Direct |
58,188
-25.0%
|
-
|
|
Sep 20
2021
|
Jane Huang CMO, Hematology |
SELL
Open market or private sale
|
Direct |
6,000
-30.64%
|
$2,394,000
$399.96 P/Share
|
|
Sep 20
2021
|
Jane Huang CMO, Hematology |
BUY
Exercise of conversion of derivative security
|
Direct |
6,000
+50.0%
|
$714,000
$119.96 P/Share
|
|
Sep 15
2021
|
John Oyler Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
26,158
-51.27%
|
$9,887,724
$378.57 P/Share
|
|
Sep 15
2021
|
John Oyler Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
190,203
-9.87%
|
$5,515,887
$29.31 P/Share
|
|
Sep 14
2021
|
John Oyler Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
37,877
-41.69%
|
$13,862,982
$366.33 P/Share
|
|
Sep 14
2021
|
John Oyler Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
157,600
-6.5%
|
$4,412,800
$28.22 P/Share
|
|
Sep 13
2021
|
Jane Huang CMO, Hematology |
SELL
Open market or private sale
|
Direct |
12,901
-46.67%
|
$4,631,459
$359.46 P/Share
|
|
Sep 10
2021
|
Amgen Inc > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
165,529
+0.87%
|
$49,989,758
$302.06 P/Share
|
|
Sep 02
2021
|
Jane Huang CMO, Hematology |
SELL
Open market or private sale
|
Direct |
545
-100.0%
|
$178,215
$327.18 P/Share
|
|
Sep 02
2021
|
John Oyler Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
24,499
-35.78%
|
$8,035,672
$328.65 P/Share
|
|
Sep 01
2021
|
Jane Huang CMO, Hematology |
BUY
Grant, award, or other acquisition
|
Direct |
545
+50.0%
|
-
|
|
Sep 01
2021
|
Jane Huang CMO, Hematology |
SELL
Open market or private sale
|
Direct |
542
-100.0%
|
$168,020
$310.53 P/Share
|
|
Sep 01
2021
|
Jane Huang CMO, Hematology |
BUY
Grant, award, or other acquisition
|
Direct |
7,124
+2.23%
|
-
|
|
Sep 01
2021
|
John Oyler Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
25,501
-51.85%
|
$8,287,825
$325.99 P/Share
|
|
Sep 01
2021
|
John Oyler Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
127,558
-1.73%
|
$3,061,392
$24.53 P/Share
|
|
Aug 31
2021
|
Jane Huang CMO, Hematology |
BUY
Grant, award, or other acquisition
|
Direct |
542
+50.0%
|
-
|
|
Aug 31
2021
|
Jane Huang CMO, Hematology |
BUY
Grant, award, or other acquisition
|
Direct |
7,163
+2.29%
|
-
|
|
Aug 31
2021
|
John Oyler Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
34,281
-28.61%
|
$10,387,143
$303.69 P/Share
|
|
Aug 31
2021
|
John Oyler Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
76,800
-2.04%
|
$1,766,400
$23.67 P/Share
|
|
Aug 05
2021
|
John Oyler Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
10,362
-23.63%
|
$3,502,356
$338.07 P/Share
|
|
Aug 05
2021
|
John Oyler Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
34,100
-0.8%
|
$852,500
$25.82 P/Share
|
|
Aug 04
2021
|
John Oyler Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
31,747
-47.77%
|
$10,920,968
$344.77 P/Share
|
|
Aug 04
2021
|
John Oyler Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
49,100
-1.11%
|
$1,276,600
$26.08 P/Share
|
|
Aug 03
2021
|
John Oyler Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
41,959
-13.83%
|
$14,014,306
$334.29 P/Share
|
|
Aug 03
2021
|
John Oyler Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
41,400
-0.85%
|
$1,035,000
$25.17 P/Share
|
|
Jul 22
2021
|
John Oyler Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
11,316
-23.24%
|
$3,564,540
$315.58 P/Share
|
|
Jul 22
2021
|
John Oyler Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
57,900
-1.05%
|
$1,331,700
$23.71 P/Share
|
|
Jul 21
2021
|
John Oyler Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
15,260
-40.83%
|
$4,715,340
$309.11 P/Share
|
|
Jul 21
2021
|
John Oyler Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
11,900
-0.21%
|
$285,600
$24.58 P/Share
|
|
Jul 20
2021
|
John Oyler Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
15,995
-47.61%
|
$5,102,405
$319.54 P/Share
|
|
Jul 20
2021
|
John Oyler Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
27,700
-0.47%
|
$664,800
$24.61 P/Share
|
|
Jul 15
2021
|
Jane Huang CMO, Hematology |
SELL
Open market or private sale
|
Direct |
21,000
-62.84%
|
$6,993,000
$333.21 P/Share
|
|
Jul 15
2021
|
Jane Huang CMO, Hematology |
BUY
Exercise of conversion of derivative security
|
Direct |
21,000
+35.32%
|
$3,171,000
$151.6 P/Share
|
|
Jul 08
2021
|
John Oyler Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
15,881
-30.67%
|
$5,050,158
$318.31 P/Share
|
|
Jul 08
2021
|
John Oyler Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
51,300
-0.84%
|
$1,231,200
$24.24 P/Share
|
|
Jul 07
2021
|
John Oyler Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
26,046
-29.71%
|
$8,256,582
$317.49 P/Share
|
|
Jul 07
2021
|
John Oyler Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
40,700
-0.64%
|
$1,017,500
$25.14 P/Share
|
|
Jul 06
2021
|
Xiaobin Wu President, COO & GM China |
SELL
Open market or private sale
|
Direct |
10,180
-48.22%
|
$3,318,680
$326.45 P/Share
|
|
Jul 06
2021
|
John Oyler Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
13,075
-46.1%
|
$4,262,450
$326.28 P/Share
|
|
Jul 06
2021
|
John Oyler Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
44,300
-0.65%
|
$1,107,500
$25.42 P/Share
|
|
Jul 01
2021
|
Julia Aijun Wang Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
308
-100.0%
|
$107,492
$349.06 P/Share
|
|
Jul 01
2021
|
Xiaodong Wang Director |
SELL
Open market or private sale
|
Direct |
4,848
-45.42%
|
$1,682,256
$347.5 P/Share
|